Skip To Main Content
Publications icon

Publications

Visit PubMed.gov to browse a listing of published scientific literature about Tecentriq®.

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Balar AV, Galsky MD, Rosenberg JE, et al. Lancet 2017;389:67-76.

VIEW

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
Felip E, Altorki N, Zhou C, et al. Lancet 2021 Oct 9;398(10308):1344-1357.

VIEW

Atezolizumab for first-line treatment of pd-l1-selected patients with NSCLC
Herbst RS, Giaccone G, de Marinis F, et al. N Engl J Med 2020 Oct 1;383(14):1328-1339.

VIEW

Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC
Socinski MA, Jotte RM, Cappuzzo F, et al. N Engl J Med 2018;378:2288- 2301.

VIEW

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
West H, McCleod M, Hussein M, et al. Lancet Oncol 2019 Jul;20(7):924-937.

VIEW

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Rittmeyer A, Barlesi F, Waterkamp D, et al. Lancet 2017;389:255-265.

VIEW

First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer
Horn L, Mansfield A, Szczesna A, et al. N Engl J Med 2018 Dec 6;379(23):2220-2229.

VIEW

Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn RS, Qin S, Ikeda M, et al. N Engl J Med 2020 May 14;382(20):1894-1905.

VIEW

Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
Gutzmer R, Stroyakovskiy D, Gogas H, et al. Lancet 2020;395:1835-1844.

VIEW

Scientific congresses icon

Scientific Congresses

Genentech maintains a presence at in-person and virtual scientific congresses worldwide. Find Genentech-sponsored posters and presentations from recent congresses at Medically.gene.com.

September 21-25, 2022
Onsite/virtual

September 29-October 1, 2022
Onsite/virtual

October 23-26, 2022
Onsite/virtual

October 28-29, 2022
Onsite

November 4-8, 2022
Onsite/virtual

November 13-16, 2022
Onsite

December 2-4, 2022
Onsite/virtual

December 6-10, 2022
Onsite/virtual

December 7-9, 2022
Onsite/virtual

Clinical trials icon

Clinical Trials

Find information about active clinical research for Tecentriq® at ClinicalTrials.gov and information about our research at Genentech Clinical Trials.

Additional resources icon

Additional Resources

For additional information or assistance regarding Tecentriq®, use the links below.

Connect with a Medical Science Liaison

Browse the Genentech Medical Information Library

Oncology at Genentech

Oncology at Roche